Shares of Exelixis, Inc. (NASDAQ:EXEL) have received a consensus recommendation of “Buy” from the fifteen ratings firms that are covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $32.57.
Several brokerages recently commented on EXEL. Oppenheimer reaffirmed a “hold” rating on shares of Exelixis in a research report on Thursday, January 4th. BidaskClub cut Exelixis from a “buy” rating to a “hold” rating in a research report on Friday, January 19th. William Blair reaffirmed an “outperform” rating on shares of Exelixis in a research report on Monday, February 12th. Cann reaffirmed a “hold” rating on shares of Exelixis in a research report on Thursday, January 4th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $38.00 target price on shares of Exelixis in a research report on Thursday, December 21st.
Shares of Exelixis (NASDAQ:EXEL) traded down $0.60 during mid-day trading on Friday, reaching $29.18. The company had a trading volume of 1,490,400 shares, compared to its average volume of 2,744,590. The company has a market capitalization of $8,690.00, a PE ratio of 59.76, a P/E/G ratio of 0.82 and a beta of 1.84. Exelixis has a 52-week low of $18.03 and a 52-week high of $32.50.
In other Exelixis news, Director Alan M. Garber sold 15,000 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total transaction of $454,500.00. Following the completion of the transaction, the director now directly owns 64,829 shares in the company, valued at $1,964,318.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.10% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. Mark Sheptoff Financial Planning LLC acquired a new position in shares of Exelixis during the 3rd quarter worth approximately $120,000. Sigma Planning Corp bought a new stake in shares of Exelixis in the 4th quarter worth approximately $208,000. American International Group Inc. bought a new position in Exelixis in the 4th quarter valued at approximately $208,000. Fisher Asset Management LLC bought a new position in Exelixis in the 3rd quarter valued at approximately $213,000. Finally, Klingenstein Fields & Co. LLC bought a new position in Exelixis in the 4th quarter valued at approximately $213,000. Hedge funds and other institutional investors own 79.48% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/20/exelixis-inc-exel-receives-32-57-average-pt-from-analysts.html.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.